# EDGAR Filing Document

**Accession Number:** 0001980648
**File Stem:** 0001980648-25-000006
**Filing Date:** 2025-12
**Character Count:** 8750
**Document Hash:** 060ded5b0ed5234ffea5fcb474fafec0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001980648-25-000006.hdr.sgml**: 20251212

**ACCESSION NUMBER**: 0001980648-25-000006

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251210

**FILED AS OF DATE**: 20251212

**DATE AS OF CHANGE**: 20251212

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lee Chan Henry
- **CENTRAL INDEX KEY:** 0001980648

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37686
- **FILM NUMBER:** 251568905

**MAIL ADDRESS:**
- **STREET 1:** 55 CAMBRIDGE PARKWAY
- **STREET 2:** SUITE 700W
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BeOne Medicines Ltd.
- **CENTRAL INDEX KEY:** 0001651308
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981209416
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O BEONE MEDICINES I GMBH
- **STREET 2:** AESCHENGRABEN 27, 21ST FLOOR
- **CITY:** BASEL
- **PROVINCE COUNTRY:** V8
- **ZIP:** 4051
- **BUSINESS PHONE:** 41-616851900

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O BEONE MEDICINES I GMBH
- **STREET 2:** AESCHENGRABEN 27, 21ST FLOOR
- **CITY:** BASEL
- **PROVINCE COUNTRY:** V8
- **ZIP:** 4051

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BeiGene, Ltd.
- **DATE OF NAME CHANGE:** 20150819

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lee Chan Henry<br><sub>(Last) (First) (Middle)</sub><br>C/O BEONE MEDICINES I GMBH<br>AESCHENGRABEN 27, 21ST FLOOR<br><sub>(Street)</sub><br>BASEL, V8 4051<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-12-10 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_SVP, General Counsel_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>BeOne Medicines Ltd. [ ONC ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares |  |  |  |  |  |  |  | 223106 | D |  |
| American Depositary Shares<sup>(1)</sup> | 2025-12-10 |  | M |  | 101 | A | $194.47 | 101 | D |  |
| American Depositary Shares<sup>(1)</sup> | 2025-12-10 |  | M |  | 133 | A | $213.32 | 234 | D |  |
| American Depositary Shares<sup>(1)</sup> | 2025-12-10 |  | M |  | 98 | A | $159.03 | 332 | D |  |
| American Depositary Shares<sup>(1)</sup> | 2025-12-10 |  | S<sup>(2)</sup> |  | 332 | D | $318.28 | 0 | D |  |
| American Depositary Shares<sup>(1)</sup> | 2025-12-11 |  | M |  | 101 | A | $194.47 | 101 | D |  |
| American Depositary Shares<sup>(1)</sup> | 2025-12-11 |  | M |  | 133 | A | $213.32 | 234 | D |  |
| American Depositary Shares<sup>(1)</sup> | 2025-12-11 |  | M |  | 98 | A | $159.03 | 332 | D |  |
| American Depositary Shares<sup>(1)</sup> | 2025-12-11 |  | S<sup>(2)</sup> |  | 332 | D | $325 | 0 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Share Option (Right to Buy) | 14.96<sup>(3)</sup> | 2025-12-10 |  | M |  |  | 1313 | <sup>(4)</sup> | 2032-08-04 | Ordinary Shares | 1313 | $0 | 34385 | D |  |
| Share Option (Right to Buy) | 16.41<sup>(3)</sup> | 2025-12-10 |  | M |  |  | 1729 | <sup>(5)</sup> | 2033-06-14 | Ordinary Shares | 1729 | $0 | 102206 | D |  |
| Share Option (Right to Buy) | 12.23<sup>(3)</sup> | 2025-12-10 |  | M |  |  | 1274 | <sup>(6)</sup> | 2034-06-04 | Ordinary Shares | 1274 | $0 | 121940 | D |  |
| Share Option (Right to Buy) | 14.96<sup>(3)</sup> | 2025-12-11 |  | M |  |  | 1313 | <sup>(4)</sup> | 2032-08-04 | Ordinary Shares | 1313 | $0 | 33072 | D |  |
| Share Option (Right to Buy) | 16.41<sup>(3)</sup> | 2025-12-11 |  | M |  |  | 1729 | <sup>(5)</sup> | 2033-06-14 | Ordinary Shares | 1729 | $0 | 100477 | D |  |
| Share Option (Right to Buy) | 12.23<sup>(3)</sup> | 2025-12-11 |  | M |  |  | 1274 | <sup>(6)</sup> | 2034-06-04 | Ordinary Shares | 1274 | $0 | 120666 | D |  |

---

### Footnotes:

(1) Each American Depositary Share represents 13 Ordinary Shares.

(2) The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.

(3) The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

(4) These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

(5) These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

(6) These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

**Signature:** /s/ Qing Nian, as Attorney-in-Fact  
**Date:** 2025-12-12

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**